Tyrell J Simkins1,2,3, Greg J Duncan4,5, Dennis Bourdette4,5. 1. Department of Neurology, Oregon Health and Science University, 3181S W Sam Jackson Rd L226, Portland, OR, 97239, USA. simkinst@ohsu.edu. 2. Jungers Center for Neurosciences Research, Oregon Health and Science University, Portland, OR, USA. simkinst@ohsu.edu. 3. Department of Neurology, Portland VA Medical Center, Portland, OR, USA. simkinst@ohsu.edu. 4. Department of Neurology, Oregon Health and Science University, 3181S W Sam Jackson Rd L226, Portland, OR, 97239, USA. 5. Jungers Center for Neurosciences Research, Oregon Health and Science University, Portland, OR, USA.
Abstract
PURPOSE OF REVIEW: Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system (CNS). Inflammatory attacks in MS lead to both demyelination and axonal damage. However, due to incomplete remyelination most MS lesions remain chronically demyelinated. In parallel, there is axonal degeneration in the CNS of MS patients, contributing to progressive disability. There are currently no approved therapies that adequately restore myelin or protect axons from degeneration. In this review, we will discuss the pathophysiology of axonal loss and chronic demyelination in MS and how understanding this pathophysiology is leading to the development of new MS therapeutics. RECENT FINDINGS: Ongoing research into the function of oligodendrocytes and myelin has revealed the importance of their relationship with neuronal health. Demyelination in MS leads to a number of pathophysiologic changes contributing to axonal generation. Among these are mitochondrial dysfunction, persistent neuroinflammation, and the effects of reactive oxygen and nitrogen species. With this information, we review currently approved and investigational therapies designed to restore lost or damaged myelin and protect against neuronal degeneration. The development of therapies to restore lost myelin and protect neurons is a promising avenue of investigation for the benefit of patients with MS.
PURPOSE OF REVIEW: Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system (CNS). Inflammatory attacks in MS lead to both demyelination and axonal damage. However, due to incomplete remyelination most MS lesions remain chronically demyelinated. In parallel, there is axonal degeneration in the CNS of MS patients, contributing to progressive disability. There are currently no approved therapies that adequately restore myelin or protect axons from degeneration. In this review, we will discuss the pathophysiology of axonal loss and chronic demyelination in MS and how understanding this pathophysiology is leading to the development of new MS therapeutics. RECENT FINDINGS: Ongoing research into the function of oligodendrocytes and myelin has revealed the importance of their relationship with neuronal health. Demyelination in MS leads to a number of pathophysiologic changes contributing to axonal generation. Among these are mitochondrial dysfunction, persistent neuroinflammation, and the effects of reactive oxygen and nitrogen species. With this information, we review currently approved and investigational therapies designed to restore lost or damaged myelin and protect against neuronal degeneration. The development of therapies to restore lost myelin and protect neurons is a promising avenue of investigation for the benefit of patients with MS.
Authors: Emma C Tallantyre; Lars Bø; Omar Al-Rawashdeh; Trudy Owens; Chris H Polman; James S Lowe; Nikos Evangelou Journal: Mult Scler Date: 2010-03-09 Impact factor: 6.312
Authors: Mitchell T Wallin; William J Culpepper; Jonathan D Campbell; Lorene M Nelson; Annette Langer-Gould; Ruth Ann Marrie; Gary R Cutter; Wendy E Kaye; Laurie Wagner; Helen Tremlett; Stephen L Buka; Piyameth Dilokthornsakul; Barbara Topol; Lie H Chen; Nicholas G LaRocca Journal: Neurology Date: 2019-02-15 Impact factor: 9.910
Authors: Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Marc C Ford; Olga Alexandrova; Lee Cossell; Annette Stange-Marten; James Sinclair; Conny Kopp-Scheinpflug; Michael Pecka; David Attwell; Benedikt Grothe Journal: Nat Commun Date: 2015-08-25 Impact factor: 14.919